Association of active ingredients, notably tetrahydropyridines and acetylcholinesterase inhibiting agents, for the treatment of senile dementia of the alzheimer type.

摘要

Invention Patent: B "ASSOCIATION OF ACTIVE PRINCIPLES, NOTES OF TETRA-HYDROPYRIDINES AND ACETYL CHOLINESTERASE INHIBITING AGENTS, FOR THE TREATMENT OF SENIL DEMENCE OF THE ALZHEIMER TYPE" D. The invention relates to a pharmaceutical composition containing as active ingredients: a constituent (a) selected from 1- (2-napht-2-ylethyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine and a compound (I) in which Y represents -CH- or -N-; R ~ 1 ~ represents hydrogen, a halogen, hydroxyl, CF ~ 3 ~, alkyl (C ~ 3 ~ -C ~ 4 ~) or alkoxy group (C ~ 1 ~ -C ~ 4 ~); R ~ 2 ~ represents hydrogen, halogen, hydroxyl, CF ~ 3 ~, alkyl (C ~ 3 ~ -C ~ 4 ~) or alkoxy group (C ~ 1 ~ -C ~ 4 ~); R ~ 3 ~ and R ~ 4 ~ each represent hydrogen or alkyl (C ~ 1 ~ -C ~ 4 ~); X represents (a) (C ~ 3 ~ -C ~ 6 ~) alkyl; alkoxy (C ~ 3 ~ -C ~ 6 ~); carboxyalkyl (C ~ 3 ~ -C ~ 7 ~); alkoxycarbonyl (C ~ 1 ~ -C ~ 4 ~) alkyl (C ~ 3 ~ -C ~ 6 ~); carboxyalkoxy (C ~ 3 ~ -C ~ 7 ~); or alkoxycarbonyl (C ~ 1 ~ -C ~ 4 ~) alkoxy (C ~ 3 ~ -C ~ 6 ~); (b) a radical selected from cycloalkyl (C ~ 3 ~ -C ~ 7 ~), cycloalkyloxy (C ~ 3 ~ -C ~ 7 ~), cycloalkylmethyl (C ~ 3 ~ -C ~ 7 ~), cycloalkylamino (C ~ 3 ~ -C ~ 7 ~) and cyclohexenyl, the radical mentioned capable of being substituted by halogen, hydroxy, alkoxy (C ~ 1 ~ -C ~ 4 ~), carboxy, alkoxycarbonyl (C ~ 1 ~ -C ~ 4 ~) , amino, mono- or di-alkylamino (C ~ 1 ~ -C ~ 4 ~) or (c) a group selected from phenyl, phenoxy, phenylamino, alkyl-phenyl-amino N- (C ~ 1 ~ -C ~ 3 ~), phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, the mentioned group capable of being mono- or polysubstituted in the phenyl group by a halogen, CF ~ 3 ~, alkyl (C ~ 1 ~ -C ~ 4 ~ ), alkoxy (C ~ 1 ~ -C ~ 4 ~), cyano, amino, mono- or di-alkylamino (C ~ 1 ~ -C ~ 4 ~), acylamino (C ~ 1 ~ -C ~ 4 ~), carboxy, alkoxycarbonyl (C ~ 1 ~ -C ~ 4 ~), aminocarbonyl, mono- or di-alkylaminocarbonyl (C ~ 1 ~ -C ~ 4 ~), alkyl (C ~ 1 ~ -C ~ 4 ~) amino, alkyl (C ~ 1 ~ -C ~ 4 ~) hydroxy, or (C ~ 1 ~ -C ~ 4 ~) halogen; optionally in the form of one of its pharmaceutically acceptable salts; and a constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1- (2naft-2-ylethyl) -4- (3- trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine or one of its pharmaceutically acceptable salts, constituent (b) is an acetylcholinesterase inhibiting agent.